Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Q1 2026 earnings

Reported May 7, 2026 · After market close

Revenue$10.9MBeat by $169.6K
EPS-$1.82Miss by $0.08
Revenue estimate$10.7M
EPS estimate-$1.74

Next report

Aug 6, 2026 (In 1 week)
Revenue estimate$10.4M
EPS estimate-$1.94

Financials

Q1 2026

Income statement

See full
Revenue$10.9M+3.8%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation & ratios

Valuation

as of 07/28/26
See full
Market cap$2.41B+489%
Enterprise value$2.49B+399%
P/S43.3×+37.9×

Profitability

See full
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Segments

By product

See full
Non Cash Royalty Revenue Related To Sale Of Future Royalties$10.9M+3.8%

Versus estimates

Revenue

Q1 2026$10.9MBeat by $169.6K
Q4 2025$21.8MBeat by $11.6MQ3 2025$11.8MBeat by $1.4MQ2 2025$11.2MBeat by $1.8MQ1 2025$10.5MMiss by $4.9MQ4 2024$29.2MMiss by $7.5M

Diluted EPS

Q1 2026-$1.82Miss by $0.08
Q4 2025-$1.78Beat by $0.98Q3 2025-$1.85Beat by $1.00Q2 2025-$2.95Beat by $0.18Q1 2025-$3.30Miss by $0.60Q4 2024-$2.25Miss by $0.30

Ask the moment Nektar Therapeutics reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did Nektar Therapeutics report Q1 2026 earnings?
Nektar Therapeutics (NKTR) reported Q1 2026 earnings on May 7, 2026 after market close.
What were Nektar Therapeutics's Q1 2026 revenue and EPS?
Nektar Therapeutics reported revenue of $10.9M and eps of $-1.82 for Q1 2026.
Did Nektar Therapeutics beat estimates in Q1 2026?
Revenue beat the consensus estimate of $10.7M by $169.6K. EPS missed the consensus estimate of $-1.74 by $0.08.
How did Nektar Therapeutics's Q1 2026 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 3.8% from $10.5M a year earlier and eps grew 44.8% from $-3.30.
Where can I find Nektar Therapeutics's Q1 2026 SEC filings?
You can read the 8-K earnings release (0001213900-26-053369) and the 10-Q periodic report (0001193125-26-212596) directly on SEC EDGAR. The filing index links above go to sec.gov.